home / stock / clrb / clrb news

CLRB News and Press, Cellectar Biosciences Inc. From 08/15/19

Stock Information
Company Name: Cellectar Biosciences Inc.
Stock Symbol: CLRB
Market: NASDAQ
Website: cellectar.com
Menu
CLRB CLRB Quote CLRB Short CLRB News CLRB Articles CLRB Message Board
Get CLRB Alerts

News, Short Squeeze, Breakout and More Instantly...
CLRB - Cellectar Appoints Dov Elefant as Chief Financial Officer

FLORHAM PARK, N.J., Aug. 15, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the appointment of Mr. Dov Elef...
CLRB - CLR 131 Advances to Second Malignant Brain Tumor Cohort of Ongoing Pediatric Phase 1 Study

FLORHAM PARK, N.J., Aug. 14, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB) , a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it has successfully completed...

CLRB - Cellectar Reports Second Quarter 2019 Financial Results and Provides a Corporate Update

FLORHAM PARK, N.J., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced financial results for the second qua...

CLRB - Two shops soften view on Pfizer in premarket analyst action

Cellectar Biosciences (NASDAQ: CLRB ) initiated with Buy rating and $6 (180% upside) price target at Brookline Capital. Shares up  8%  premarket. More news on: Cellectar Biosciences, Inc., Heat Biologics, Inc., Progenics Pharmaceuticals, Inc., Healthcare stocks news, Stocks on th...
CLRB - M&A dominate premarket gainers

Acacia Communications (NASDAQ: ACIA ) +37%  on being acquired by Cisco. More news on: Acacia Communications, Inc., Camber Energy, Inc., Check-Cap Ltd., Stocks on the move, Read more ...

CLRB - Cellectar's CRL 131 Fast Track'd for DLBCL; shares up 6% premarket

The FDA designates Cellectar Biosciences' (NASDAQ: CLRB ) lead candidate CLR 131 for Fast Track review for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). More news on: Cellectar Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ... ...

CLRB - Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma

FLORHAM PARK, N.J., July 09, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the U.S. Food and Drug Administ...
CLRB - Cellectar -5.1% on 6.02M-share holder filing

Cellectar Biosciences (NASDAQ: CLRB ) is 5.1% lower postmarket after a shareholder filing to offer up to 6.02M common shares. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, Stocks on the move, Read more ...

CLRB - NetworkNewsBreaks - Cellectar Biosciences, Inc. (NASDAQ: CLRB) Secures $10M Through RDO Sale, Private Placement

Clinical stage biopharmaceutical company Cellectar Biosciences (NASDAQ: CLRB) has closed a registered direct offering sale of 1,982,000 common shares and concurrent private placement of 2,018,000 common shares with institutional investors. In conjunction with the offerings, the company issued ...

CLRB - FCEL, STM among premarket gainers

CIRCOR (NYSE: CIR ) +51%  on Crane buyout offer . More news on: CIRCOR International, Inc., JMU Limited, Biocept, Inc., Stocks on the move, Read more ...

Previous 10 Next 10